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will be concurrent development for high-income, and 
low-income and middle-income countries.13 The need for 
maternal group B streptococcus vaccine in low-income 
and middle-income countries that do not have the 
infrastructure and resources to implement intrapartum 
antibiotic prophylaxis strategies is clear.1,14 The data 
presented by O’Sullivan and colleagues underscore 
that high-income countries also have a shared interest 
in alternatives or adjuncts to intrapartum antibiotic 
prophylaxis to protect infants from group B streptococcus.
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Primaquine for all: is it time to simplify malaria treatment in 
co-endemic areas?
In most areas endemic for malaria, the major species 
are Plasmodium falciparum and Plasmodium vivax. 
Falciparum malaria is more often lethal, develops 
resistance to drugs easily, and is responsible for most 
of the malaria burden in Africa. However, particularly 
in this second era of malaria elimination efforts,1 
P vivax requires increasing attention2 because of the 
intrinsic challenges related to its control. This species 
can lead to severe or even life-threatening disease,3 can 
present variable evidence of resistance to chloroquine 
in relation to geographical area,4 and has few drug 
options to prevent relapse. Prevention of relapse is 
essential because up to 80% of reported cases of P vivax 
malaria could result from hypnozoite-derived relapses, 
rather than from newly acquired infections.5 The 
triggers of relapse are not sufficiently understood, but 
8-aminoquinolines (such as primaquine, or the newly 
registered tafe noquine) are the only effective drugs 
enabling radical cure.
There are several sources of variation in relapse rates. 
Different strains of vivax have distinct relapse patterns,6 
and pharmacogenetics also seems to have a role in 
primaquine metabolism, which could affect relapse 
as primaquine only becomes active once metabolised 
(CYP 2D6 pathway) into its active metabolites.7 
However, acute infections may also trigger relapses.8 
Data showing possible P vivax relapses after P falciparum 
infection were obtained first in Thailand,9 but an 
analysis reported in The Lancet Infectious Diseases by 
Robert Commons and colleagues10 provides statistical 
robustness regarding this observation. Their impressive 
meta-analysis, which included 31 262 patients from 
153 studies done over more than four decades, supports 
that such relapses are not just local, but rather occur 
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globally in all settings co-endemic for P vivax and P 
falciparum. The overall risk of P vivax parasitaemia by 
day 42 after P falciparum treatment was 5·6% (95% CI 
4·0–7·4). Although the investigators found some short-
term significant differences in the risk of recurrence 
depending on regional relapse periodicity and the half-
lives of the drugs used to treat the initial P falciparum 
infection, the differential effect seemed to wane by 
day 63, when nearly a quarter (24%) of all patients 
treated for P falciparum had developed a P vivax relapse, 
detectable in peripheral blood. Importantly, P vivax 
predominated among all parasite recurrences following 
P falciparum treatment, representing about 70% of 
recurrences at day 63.
The mechanisms behind such relapses are still 
unknown, but one could argue, from a public health 
standpoint, that the time has come to propose an 
innovative move in the treatment of malaria, promoting 
the universal use of primaquine for both species in areas 
where they co-exist and remain prevalent. Indeed, 
the number of cases of P falciparum needed to treat 
with radical cure to prevent one P vivax recurrence by 
day 63—ranging between 4·7 and 5·0 as proposed by 
the study investigators—would seem to amply justify 
this radical change in malaria treatment. The additional 
P falciparum gametocidal effect that 8-aminoquinolines 
exert, which should also substantially reduce malaria 
transmission, might be another advantage of such a 
bold programmatic change.
In areas where primaquine is routinely used for all 
patients with P vivax, such as Latin America,11 this 
change would not pose major difficulties, with the 
exception of ensuring adequate compliance for a usually 
2-week treatment course. Nevertheless, in areas where 
glucose-6-phosphate dehydrogenase (G6PD) deficiency 
is prevalent, such as southeast Asia, primaquine use 
would need to be expanded carefully on account of the 
potential hazards that such a prohaemolytic drug might 
have in individuals lacking full functionality of the G6PD 
enzyme.12 The availability of point-of-care tests to detect 
G6PD deficiency (ie, G6PD activity lower than 30%) 
might help the safe use of primaquine against both 
malaria species.13
In the real world, however, the switch from a 
simple 3-day P falciparum treatment regimen with an 
artemisinin-based combination therapy (ACT) to a 
14-day course including primaquine might be met with 
some reluctance among health providers and even the 
general population. In this respect, tafenoquine could be 
an exciting alternative to bypass these barriers, because 
it only requires a single dose, and is considered safe and 
efficacious for individuals with G6PD activity higher 
than 70%.14
Studies such as the one by Commons and colleagues 
highlight the relevance of meta-analytical approaches 
to answer questions that remain difficult to solve with 
single studies. The results of this study hint at the 
exciting potential of simplifying malaria treatment 
in areas co-endemic for P falciparum and P vivax. Use 
of an ACT plus primaquine (or tafenoquine) regimen 
irrespective of the underlying species could have huge 
operational advantages, but the overall impact of such 
an approach needs to be thoroughly evaluated.
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Improving the provision of rabies post-exposure prophylaxis
In 2015, WHO and its partners set the ambitious objective1 
to reach zero human deaths from dog-mediated rabies 
by 2030, after the concept of effective One Health 
interventions.2 Mass dog vaccination is expected to 
be an important part of any successful strategy.3,4 In 
The Lancet Infectious Diseases, the WHO Rabies Modelling 
Consortium5 reminds us that effective and timely post-
exposure prophylaxis, administered to humans bitten by 
rabid dogs to prevent the fatal onset of rabies, is another 
essential tool for success.5 Through the analysis of a wide 
range of data collected in multiple countries and the use 
of multilayer mathematical models, the authors show 
that increased investment in post-exposure prophylaxis 
by Gavi, the Vaccine Alliance, would be extremely cost-
effective and could substantially reduce disease burden. 
The study is particularly timely because Gavi is currently 
reconsidering rabies vaccine investment.
Preparation of such assessment required the 
Consortium5 to overcome several major challenges. 
First, any assessment of post-exposure prophylaxis 
needs to account for a very diverse set of factors.6 For 
example, it must be based on a good understanding 
of dog populations, how they are structured, how 
they interact with humans, how they can be affected 
by the spread of rabies, and how that spread might 
be mitigated by dog vaccination.7 Furthermore, the 
likelihood that a bitten person will seek, obtain access 
to, and complete post-exposure prophylaxis treatment 
depends on cultural, economic, geographical, and 
logistical factors (eg, awareness in the population, 
accessibility to post-exposure prophylaxis centres, direct 
and indirect costs, effective stockpiling, and delivery of 
vaccines). Several of these factors have historically been 
poorly characterised and might exhibit strong spatial 
heterogeneities. A major strength of the analysis5 is that 
it benefited from tremendous efforts by Gavi to reduce 
some of these knowledge gaps by supporting rabies field 
studies. Consequently, the diversity of data the authors 
used to build their assessment is quite impressive, 
both in terms of data type and geographical coverage. 
A second achievement of the paper is that the authors 
developed a multidisciplinary modelling framework 
in which these data could be integrated in a coherent 
way, making it possible to generate rabies incidence 
dynamics in dogs and the associated human exposures 
under various epidemiological scenarios, while also 
capturing economic, behavioural, and logistical aspects.5
The new data and modelling framework therefore 
constitute an important improvement to past 
studies; future iterations of the work are likely to lead 
to additional refinements. Of course, still too many 
countries have little or no data available, and more field 
studies targeting these places are needed. Some aspects 
of the assessment could also be improved further. For 
example, in some circumstances, free provision alone 
might be insufficient to increase health-care seeking 
and accessibility. Indeed, the lack of infrastructure might 
make it impossible for exposed populations (especially 
those living in rural remote areas) to travel to clinics and 
access post-exposure prophylaxis,8 even if vaccines are 
freely available. To this regard, further investments are 
needed to improve the accessibility to post-exposure 
prophylaxis via point-of-care and decentralised 
integrated dog bite management centres (IDBCs).9 The 
geographical distribution of these IDBCs is a crucial issue 
in many developing countries and will require important 
efforts from national authorities.8 The education of 
populations to increase awareness and perception 
of the risks related to dog bite exposure and rabies is 
another complex issue that is starting to be addressed 
by stakeholders but should be promoted further.10
Hopefully, Gavi and other national and international 
stakeholders and donors will keep on supporting 
field studies so that all these aspects can be better 
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